Ignite Creation Date:
2025-12-24 @ 5:55 PM
Ignite Modification Date:
2026-02-25 @ 9:40 PM
Study NCT ID:
NCT02284568
Status:
COMPLETED
Last Update Posted:
2022-03-10
First Post:
2014-10-31
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Organization: